Holzer Holzer & Fistel, LLC Announces Investigation Into The Proposed Buyout Of ISTA Pharmaceuticals, Inc.

Holzer Holzer & Fistel, LLC is investigating whether the directors of ISTA Pharmaceuticals, Inc. (“ISTA” or the “Company”) (NASDAQ: ISTA) complied with their fiduciary duties in approving the proposed acquisition of the Company by Bausch & Lomb. According to the Company’s announcement, if the deal closes ISTA shareholders will receive $9.10 per share of ISTA owned. The investigation seeks to determine, among other things, whether the consideration to be paid to ISTA shareholders is fair and adequate.

Current holders of ISTA common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

Copyright Business Wire 2010

If you liked this article you might like

Stocks to Watch: Opnext, Ista (Update 1)

Apollo, Opnext: After-Hours Trading (Update 1)

10 Small-Cap Stocks Poised to Rise, History Shows (Update2)

Valeant Pulls Ista Pharma Takeout Bid

Stocks End Higher on Global Data